This study is testing a new way to deliver radiation therapy called Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for cancers in the central part of the lung. This treatment uses a special MRI-guided machine to deliver radiation more precisely, aiming to improve safety while keeping it effective. Researchers want to see if this approach, which involves 5 radiation treatments given every three weeks, can improve how well tumors are seen and reduce side effects. You might be able to join if you are at least 18 years old and have a confirmed cancer diagnosis with a lung tumor that meets specific size and location requirements. The study will look at how long participants survive and how their tumors respond over 4 years. The current status of this study is unclear, and it plans to enroll 30 participants.

Study design

This is a single-arm feasibility study, meaning all 30 participants will receive the same treatment. It is not specified if it is blinded.

What's involved

You would receive 5 radiation treatments, with one treatment given every 3 weeks. The study does not specify other visits, procedures, or tests.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for survivability and response for 4 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.